- Titel
- Immunogenicity and protective efficacy of novel mucosal inactivated RSV vaccines
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa2-1030031
- Datum der Einreichung
- 02.07.2024
- Datum der Verteidigung
- 27.01.2026
- Abstract (EN)
- The last years have been marked by the SRAS-CoV-2 pandemic as well as the previous centuries by diverse respiratory virus outbreaks. This highlights the need for fast mucosal vaccines to combat pathogens. Mucosal vaccines induce superior local immune responses, provide better protection, and reduced virus shedding compared to systemic vaccines. They can be self-administered, leading to faster herd immunity. The atraumatic nature of mucosal vaccination also enhances vaccine compliance. This thesis provides valuable insights to improve mucosal vaccine approaches and help in a fast fight against pandemics. The aim of this thesis was to induce protection against RSV infection with a mucosally applied inactivated whole virus vaccine. An inactivated whole virus expresses all viral surface proteins, electing a broader immune response and by the mucosal vaccination route both local mucosal and systemic protection in mice. LEEI was used for the inactivation as it offers an improved surface protein conservation compared to other irradiation or chemical inactivation methods. To prevent interception at the mucosal surface without inducing an immune response, a liposome formulation to encapsulate the vaccine and enhance immunogenicity was used. To evaluate the protective efficacy, the vaccine was tested in a homologous vaccination trial followed by an RSV challenge in mice. In an additional animal trial, two different formulations were comped and comprehensive analysis of the immune system were conducted to ensure the absence of adverse effects following immunization and challenge. Control groups, including sham treated and intramuscular vaccinated animals, were included in both trials to ensure the effectiveness of the LEEI-RSV vaccine. Furthermore, FI-RSV was used in the second trial as a comparison for adverse immunological effects. The analysis and findings of this thesis are highly significant in addressing unanswered questions regarding the combination of mucosal vaccines and consecutive challenge against RSV which can be transferred to other respiratory viruses. Furthermore, a combination of LEEI inactivated pathogens and the identified potent formulations may serve as a platform technology for other respiratory virus vaccines.
- Forschungsdatenverweis
- Mucosal Application of a Low-Energy Electron Inactivated Respiratory Syncytial Virus Vaccine Shows Protective Efficacy in an Animal Model
DOI: http://doi.org/10.3390/v15091846 - Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias
DOI: 10.3389/fimmu.2024.1382318 - Freie Schlagwörter (EN)
- Mucosal Vaccines', 'Mucosal Immunsystem', 'Respiratory Snycical Virus (RSV)', 'Vaccine Formulation
- Klassifikation (DDC)
- 610
- Den akademischen Grad verleihende / prüfende Institution
- Universität Leipzig, Leipzig
- Version / Begutachtungsstatus
- angenommene Version / Postprint / Autorenversion
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa2-1030031
- Veröffentlichungsdatum Qucosa
- 12.03.2026
- Dokumenttyp
- Dissertation
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0